Recently, Zacks.com users have been paying close attention to Intuitive Surgical (ISRG). This makes it worthwhile to examine what the stock has in store.
Intuitive Surgical stock gains after Q4 EPS and revenue top estimates as system placements and procedure growth offset a decline in gross margin.
Robotic-assisted surgery stalwart Intuitive Surgical NASDAQ: ISRG blew investors away with its Q3 2025 earnings report back in October 2025. Shares closed up nearly 14% in reaction to the results, marking the healthcare stock's largest single-day post-earnings gain in recent memory.
Although the revenue and EPS for Intuitive Surgical (ISRG) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Intuitive Surgical reported strong Q4 2025 outcomes with adjusted EPS of $2.53, exceeding estimates of $2.26 and increasing by 14.5% from Q4 2024's $2.21. Revenue reached $2.87 billion, a 19% increase year-over-year that surpassed the consensus of $2.75 billion, while full-year revenue hit $10.1 billion (+21%) coupled with adjusted EPS of $8.93.
Although the revenue and EPS for Intuitive Surgical (ISRG) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Intuitive Surgical, Inc. (ISRG) Q4 2025 Earnings Call Transcript
Intuitive Surgical, Inc. (ISRG) came out with quarterly earnings of $2.53 per share, beating the Zacks Consensus Estimate of $2.25 per share. This compares to earnings of $2.21 per share a year ago.
Intuitive Surgical on Thursday beat Wall Street estimates for fourth-quarter profit and revenue on growing demand for its surgical robots used in minimally invasive procedures.
Intuitive Surgical's pure-play robotics focus, rising da Vinci 5 utilization and 85% recurring revenues tilt the risk-reward versus diversified Medtronic.
ISRG heads into Q4 earnings with 18% procedure growth and da Vinci 5 demand, but valuation and tariffs keep the earnings outlook uncertain.
ISRG posts strong preliminary Q4 and full-year 2025 revenue growth, but shares dip as investors weigh procedure trends, margins and outlook.